Impact and cost-effectiveness of rotavirus vaccination in Bangladesh

Clint Pecenka, Umesh Parashar, Jacqueline E Tate, Jahangir A M Khan, Devin Groman, Stephen Chacko, Md Shamsuzzaman, Andrew Clark, Deborah Atherly, Clint Pecenka, Umesh Parashar, Jacqueline E Tate, Jahangir A M Khan, Devin Groman, Stephen Chacko, Md Shamsuzzaman, Andrew Clark, Deborah Atherly

Abstract

Introduction: Diarrheal disease is a leading cause of child mortality globally, and rotavirus is responsible for more than a third of those deaths. Despite substantial decreases, the number of rotavirus deaths in children under five was 215,000 per year in 2013. Of these deaths, approximately 41% occurred in Asia and 3% of those in Bangladesh. While Bangladesh has yet to introduce rotavirus vaccination, the country applied for Gavi support and plans to introduce it in 2018. This analysis evaluates the impact and cost-effectiveness of rotavirus vaccination in Bangladesh and provides estimates of the costs of the vaccination program to help inform decision-makers and international partners.

Methods: This analysis used Pan American Health Organization's TRIVAC model (version 2.0) to examine nationwide introduction of two-dose rotavirus vaccination in 2017, compared to no vaccination. Three mortality scenarios (low, high, and midpoint) were assessed. Benefits and costs were examined from the societal perspective over ten successive birth cohorts with a 3% discount rate. Model inputs were locally acquired and complemented by internationally validated estimates.

Results: Over ten years, rotavirus vaccination would prevent 4000 deaths, nearly 500,000 hospitalizations and 3 million outpatient visits in the base scenario. With a Gavi subsidy, cost/disability adjusted life year (DALY) ratios ranged from $58/DALY to $142/DALY averted. Without a Gavi subsidy and a vaccine price of $2.19 per dose, cost/DALY ratios ranged from $615/DALY to $1514/DALY averted.

Conclusion: The discounted cost per DALY averted was less than the GDP per capita for nearly all scenarios considered, indicating that a routine rotavirus vaccination program is highly likely to be cost-effective. Even in a low mortality setting with no Gavi subsidy, rotavirus vaccination would be cost-effective. These estimates exclude the herd immunity benefits of vaccination, so represent a conservative estimate of the cost-effectiveness of rotavirus vaccination in Bangladesh.

Keywords: Bangladesh; Cost-effectiveness; DALY; Rotavirus; Vaccination.

Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
One-way sensitivity analysis of cost per DALY over 10 Years.

References

    1. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet (London, England) 2015;385:430–40. .
    1. Tate J.E., Burton A.H., Boschi-Pinto C., Parashar U.D. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis. 2016;62:S96–S105.
    1. Institute for Health Metrics and Evaluation (IHME). GBD compare data visualization. Seattle (WA): IHME, University of Washington. Available at: <>; 2016 [accessed 20.01.17].
    1. World Health Organization. Rotavirus deaths by country 2000–2013. Available at: <> [accessed 08.02.2017].
    1. International Vaccine Access Center Johns Hopkins Bloomberg School of Public Health. State of rotavirus vaccine use and impact evaluations. Baltimore; 2016.
    1. Gavi The vaccine alliance. Rotavirus vaccine support. Gavi vaccine alliance support webpage. Available at: <> 2016 [accessed 20.01.17]
    1. Strategic Advisory Group of Experts (SAGE). Meeting of the immunization strategic advisory group of experts – conclusions and recommendations. Wkly Epidemiol Rec. April 2009;2009(84):220–236.
    1. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet (London, England) 2010;376:615–23. .
    1. DefeatDD. Bangladesh: ORS and rotavirus vaccines. DefeatDD Ctry success stories 2016. Available at: <> [accessed 20.01.17]
    1. Clark A., Jauregui B., Griffiths U., Janusz C.B., Bolanos-Sierra B., Hajjeh R. TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination. Vaccine. 2013;31(Suppl 3):C19–C29.
    1. Diop A., Atherly D., Faye A., Lamine Sall F., Clark A.D., Nadiel L. Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: a country-led analysis. Vaccine. 2015;33(Suppl 1):A119–A125.
    1. Sigei C., Odaga J., Mvundura M., Madrid Y., Clark A.D. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda. Vaccine. 2015;33(Suppl 1):A109–A118.
    1. Bar-Zeev N., Tate J.E., Pecenka C., Chikafa J., Mvula H., Wachepa R. Cost-effectiveness of monovalent rotavirus vaccination of infants in Malawi: a postintroduction analysis using individual patient-level costing data. Clin Infect Dis. 2016;62(Suppl 2):S220–S228.
    1. Ahmeti A., Preza I., Simaku A., Nelaj E., Clark A.D., Felix Garcia A.G. Cost-effectiveness of rotavirus vaccination in Albania. Vaccine. 2015;33(Suppl 1):A201–A208.
    1. Javanbakht M., Moradi-Lakeh M., Yaghoubi M., Esteghamati A., Mansour Ghanaie R., Mahmoudi S. Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran. Vaccine. 2015;33(Supplement 1):A192–A200. doi: 10.1016/j.vaccine.2014.12.035.
    1. Uruena A., Pippo T., Betelu M.S., Virgilio F., Hernandez L., Giglio N. Cost-effectiveness analysis of rotavirus vaccination in Argentina. Vaccine. 2015;33(Suppl 1):A126–A134.
    1. United Nations Department of Economic and Social Affairs Population Division. World population prospects: the 2012 revision, volume 1: Comprehensive tables. New York. Available at: <>; 2013 [accessed 20.01.2017].
    1. UN Inter-agency Group for Child Mortality Estimation (IGME). Child mortality estimates: CME Info. Available from: <>; 2016 [accessed 20.01.17].
    1. Bilcke J., Van Damme P., Van Ranst M., Hens N., Aerts M., Beutels P. Estimating the incidence of symptomatic rotavirus infections: a systematic review and meta-analysis. PLoS One. 2009;4:e6060.
    1. Platts-Mills J.A., Babji S., Bodhidatta L., Gratz J., Haque R., Havt A. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED) Lancet Glob Heal. 2015;3:e564–e575.
    1. James Platts-Mills. Personal Communication. 5 August, 2016.
    1. Salomon J.A., Haagsma J.A., Davis A., de Noordhout C.M., Polinder S., Havelaar A.H. Disability weights for the global burden of disease 2013 study. Lancet Glob Heal. 2017;3:e712–e723.
    1. Sanderson C, Clark A, Taylor D, Bolanos B. Global review of rotavirus morbidity and mortality data by age and region. 2011:1–42. Available from: <> [accessed 20.01.17].
    1. World Health Organization (WHO). WHO-UNICEF estimates of DTP3 coverage 2016. Available from: <> [accessed 20.01.2017]
    1. Zaman K, Sack DA, Neuzil KM, Yunus M, Moulton LH, Sugimoto JD, et al. Effectiveness of a rotavirus vaccination program after introduction of a live oral human rotavirus vaccine in Bangladesh: a cluster-randomized trial. PLOS Med. Unpublished results.
    1. Gavi The Vaccine Alliance. Guidelines and forms: rotavirus vaccine application guidelines package 2016. Available from: <> [accessed 20.01.17].
    1. Gavi The Vaccine Alliance. Gavi, the vaccine alliance co-financing policy version 2.0. 2016. Available from: <> [accessed 20.01.17].
    1. Government of People’s Republic of Bangladesh. Comprehensive multi-year plan national immunization program of Bangladesh 2014–2018; n.d.
    1. Das S.K., Nasrin D., Ahmed S., Wu Y., Ferdous F., Farzana F.D. Health care-seeking behavior for childhood diarrhea in Mirzapur, rural Bangladesh. Am J Trop Med Hyg. 2013;89:62–68.
    1. National Institute of Population Research and Training (NIPORT), Mitra and Associates, ICF International. Bangladesh demographic and health survey 2014. Dhaka, Bangladesh and Rockville, Maryland, USA. Available from: <>; 2016 [accessed 20.01.17].
    1. Das J., Das S.K., Ahmed S., Ferdous F., Farzana F.D., Sarker M.H.R. Determinants of percent expenditure of household income due to childhood diarrhoea in rural Bangladesh. Epidemiol Infect. 2015;143:2700–2706.
    1. Rheingans R., Kukla M., Faruque A.S.G., Sur D., Zaidi A.K.M., Nasrin D. Determinants of household costs associated with childhood diarrhea in 3 South Asian settings. Clin Infect Dis. 2012;55(Suppl 4):S327–S335.
    1. Ahmed S, et al. The economic burden of rotavirus infection resulting in hospitalization among children <5 years of age in selected hospitals in Bangladesh. Unpublished results.
    1. The World Bank. Official exchange rate (LCU per US$, period average) n.d. Available from: <> [accessed 20.01.17].
    1. US Bureau of Labor Statistics. CPI inflation calculator n.d. Available from: <> [accessed 20.01.17].
    1. Marseille E., Larson B., Kazi D.S., Kahn J.G., Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118–124.
    1. Bertram M.Y., Lauer J.A., De Joncheere K., Edejer T., Hutubessy R., Kieny M.-P. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94:925–930.
    1. World Bank Group. World Data Bank n.d. Available from: <> [accessed 20.01.17].
    1. Atherly D.E., Lewis K.D.C., Tate J., Parashar U.D., Rheingans R.D. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011–2030. Vaccine. 2012;30(Suppl 1):A7–A14.
    1. Gavi The Vaccine Alliance. Joint appraisal report Bangladesh; 2016.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever